US SEC Filings Daily Market Digest — May 07, 2026

07-05-2026

EXOZYMES INC. (EXOZ) filed an 8-K on May 7, 2026, under Items 8.01 and 9.01, announcing an Investor Presentation dated May 7, 2026, provided to potential underwriters and investors for a proposed public offering of securities. The presentation is attached as Exhibit 99.1. No financial results or performance metrics are disclosed in the filing.

• ·Registrant is an emerging growth company.
• ·Common Stock (EXOZ) registered on Nasdaq Capital Market.
• ·Principal executive offices: 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016; Telephone: (626) 415-1488.

07-05-2026

Solid Power, Inc. published a Company Overview PowerPoint presentation on its investor relations website on May 7, 2026, intended for use in investor and analyst presentations. The presentation is furnished as Exhibit 99.1 to this Form 8-K filing under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). The filing includes forward-looking statements with associated risk factors but no specific financial metrics or performance data.

07-05-2026

Amcor plc's net sales surged 77% YoY to $5,914 million for the three months ended March 31, 2026, and 72% YoY to $17,108 million for the nine months ended, driven by the integration of the Berry acquisition. Net income attributable to Amcor increased 42% to $278 million in the quarter and 30% to $717 million for nine months. However, diluted EPS declined 12% to $0.60 from $0.68 in the quarter and 18% to $1.55 from $1.90 for nine months, amid higher amortization ($134 million vs $37 million), restructuring costs ($69 million vs $32 million), and interest expense ($170 million vs $85 million).

• ·Assets held for sale, net: $503 million as of March 31, 2026
• ·Operating cash flow for 9M FY2026: $556 million (up from $276 million YoY)
• ·Capital expenditures for 9M FY2026: $687 million
• ·Dividends declared for 9M FY2026: $894 million ($1.9375 per share)
• ·Total consideration for Berry: $10,397 million, including $7,897 million equity issued at $9.33 per share (7.25x exchange ratio)

07-05-2026

Arhaus reported Q1 2026 net revenue of $314,276, up 0.9% YoY from $311,372, with gross margin slightly down to $114,435 from $115,587. However, operating income declined sharply 60.6% YoY to $2,136 from $5,421, leading to net income of $2,223, down 54.5% from $4,882. Cash used in operating activities was $9,704 versus provided $46,515 YoY, with a large $49,510 dividend payment contributing to a $76M drop in cash and equivalents to $177,111 QoQ.

• ·Merchandise inventory increased to $369,457 from $338,806 QoQ.
• ·Client deposits rose to $271,229 from $235,943 QoQ.
• ·SG&A expenses up to $112,195 from $110,058 YoY.
• ·Capital expenditures on property, furniture and equipment: $16,880 (down from $27,621 YoY).

07-05-2026

Cross Country Healthcare, Inc. (NASDAQ: CCRN) has entered a definitive agreement to be acquired by Knox Lane for $13.25 per share in an all-cash transaction valued at $437 million, a 31% premium to the May 6, 2026 closing price and 45% premium to the 90-day volume-weighted average trading price. The transaction is expected to close in Q3 2026, subject to stockholder approval and regulatory clearances, after which the company will become privately held and cease trading on Nasdaq. No operating performance metrics were provided, but executives highlighted the strategic fit and growth potential under Knox Lane's ownership.

• ·Advisors: BofA Securities, Inc. (financial) and Davis Polk & Wardwell LLP (legal) for Cross Country; MTS Health Partners (financial) and Kirkland & Ellis LLP (legal) for Knox Lane.
• ·Company will continue operating under the Cross Country Healthcare name and brand post-transaction.
• ·Definitive proxy statement to be filed with SEC; stockholders urged to read for details.

07-05-2026

Privia Health reported strong Q1 2026 results with total revenue up 25.8% YoY to $603.8M, Practice Collections +14.6% to $914.8M, Adjusted EBITDA +36.3% to $36.7M, Implemented Providers +13.6% to 5,535, and Value-Based Care Attributed Lives +26.5% to 1,606,000. However, GAAP net income declined 27.4% YoY to $3.1M due to higher stock compensation and taxes, and net cash used in operating activities increased to $49.5M from $24.1M. The company reiterated full-year 2026 guidance for most metrics while raising Attributed Lives outlook to 1,600,000-1,625,000.

• ·Cash and cash equivalents decreased to $419.5M from $479.7M at Dec 31, 2025.
• ·Full-year 2026 guidance: Adjusted EBITDA $145M-$155M (unchanged), Practice Collections $3,650M-$3,750M (unchanged).

07-05-2026

Claritev Corporation reported Q1 2026 revenues of $244.7 million, up 5.8% YoY from $231.3 million, and Adjusted EBITDA of $146.9 million, up 3.4% YoY from $142.1 million, though the Adjusted EBITDA margin declined to 60.0% from 61.4%. However, net loss widened to $73.6 million from $71.3 million YoY, net cash used in operating activities increased to $45.8 million from $30.1 million, and free cash flow deteriorated to $(92.5) million from $(68.9) million. The company narrowed its FY2026 revenue guidance low-end to $985 million-$1 billion (from $980 million-$1 billion), with other metrics unchanged.

• ·FY2026 guidance: Capital expenditures $160 million to $170 million; Effective tax rate 24% to 28%; Free Cash Flow $0 million to $10 million
• ·Q1 2026 ended March 31, 2026; Investor Day held in March 2026
• ·Strong Q1 bookings from core offerings, provider, and government verticals

07-05-2026

22nd Century Group reported Q1 2026 net revenues of $4.1 million, up slightly 17% QoQ from $3.5 million but down 31.1% YoY from $5.956 million amid shifts away from low-margin contract manufacturing. While gross loss improved slightly QoQ to $(0.6) million and filtered cigar revenues rose QoQ to $0.9 million from $0.4 million, operating loss widened 8% QoQ to $3.0 million and 18.2% YoY to $3.039 million, with net loss at $3.3 million QoQ and improved 7.8% YoY. The company holds $9.5 million in cash with zero long-term debt and targets VLN expansion to over 5,000 stores by year-end.

• ·Pinnacle VLN supported in over 2,000 stores across 20 states with in-store marketing.
• ·Achieved near national level state authorizations for branded products.
• ·Q1 2026 total assets $30.3 million, up from $27.0 million at Dec 31, 2025.
• ·Adjusted EBITDA loss $2.6 million QoQ from $2.4 million, $2.595 million YoY from $2.320 million.

07-05-2026

Citizens Financial Services, Inc. reported net income of $10,376 thousand for the three months ended March 31, 2026, a 36.1% YoY increase from $7,621 thousand, supported by net interest income growth to $26,113 thousand (+13.5% YoY) and lower interest expense ($14,164 thousand vs. $16,012 thousand). However, total assets contracted 1.2% QoQ to $3,026,478 thousand, loans declined 2.3% QoQ to $2,275,328 thousand (net of $22,894 thousand allowance), and comprehensive income fell to $8,071 thousand from prior comprehensive gains due to a $2,305 thousand net OCI loss. Deposits rose 2.7% QoQ to $2,441,185 thousand, while borrowed funds dropped sharply 35.7% to $198,738 thousand.

• ·Noninterest-bearing deposits declined QoQ to $509,638 thousand from $516,657 thousand.
• ·Bank owned life insurance increased to $74,071 thousand from $51,501 thousand, reflecting $22,000 thousand purchase.
• ·EPS basic $2.16 for Q1 2026 vs. $1.59 YoY.
• ·Cash dividends paid $2,402 thousand at $0.500 per share.

07-05-2026

Zai Lab reported Q1 2026 total revenues of $99.6 million, down 6% YoY from $106.5 million, with product revenues declining 10% YoY to $95.6 million primarily due to ZEJULA sales dropping to $30.0 million from $49.5 million amid competitive pressures, and VYVGART slightly down to $17.6 million from $18.1 million on pricing adjustments; however, XACDURO surged to $8.6 million from $1.1 million and NUZYRA grew to $16.3 million from $15.1 million. R&D expenses rose 8% to $65.6 million and SG&A to $65.1 million, leading to an operational loss of $69.4 million and net loss of $51.0 million, up from $48.4 million YoY. Pipeline progress includes strong zoci data (62.5% iORR in SCLC brain mets) and collaborations with Amgen and Boehringer Ingelheim.

• ·Adjusted loss from operations: $51.9 million (excludes non-cash items)
• ·Zoci Phase 1b/2 enrollment for epNECs to complete in 2026; DLLEVATE enrollment H1 2027
• ·ZL-1503 Phase 1/1b first-in-human data expected H2 2026
• ·Potential NMPA approvals in 2026 for TIVDAK in cervical cancer and TTFields in pancreatic cancer
• ·Elegrobart Phase 3 bridging study enrollment completion Q3 2026 in China

07-05-2026

Walker & Dunlop, Inc. reported Q1 2026 total revenues of $301,331 thousand, up 27% YoY from $237,367 thousand, driven by loan origination fees surging 91% to $88,532 thousand and fair value of expected net cash flows from servicing up 68% to $46,773 thousand. However, property sales broker fees declined 2% YoY to $13,179 thousand, placement fees dipped 2% to $32,704 thousand, and other revenues fell 3% to $24,455 thousand, while mortgage servicing rights decreased 2% QoQ to $795,754 thousand. Net income attributable to Walker & Dunlop rose sharply to $15,871 thousand from $2,754 thousand YoY, though total expenses increased 19% YoY to $275,381 thousand amid higher personnel costs and indemnified loan expenses.

• ·Basic and diluted EPS of $0.46 for Q1 2026, up from $0.08 YoY.
• ·Net cash used in operating activities $1,143,912 thousand in Q1 2026 vs $281,108 thousand YoY.
• ·Warehouse notes payable increased to $2,535,227 thousand as of March 31, 2026 from $1,420,272 thousand QoQ.
• ·Basic weighted-average shares outstanding 33,394 thousand in Q1 2026 vs 33,264 thousand YoY.

07-05-2026

GigaCloud Technology Inc reported Q1 2026 total revenues of $359,488 (up 32% YoY from $271,906), driven by product revenues of $242,948 (+37% YoY) and service revenues of $116,540 (+24% YoY), with net income rising 40% to $38,124. Operating income increased 50% YoY to $42,479, supported by gross profit growth to $85,846 (+35% YoY), though selling and marketing expenses surged 68% to $31,242. However, operating cash flow deteriorated sharply to negative $(21,735) from $9,433 YoY, due to inventory buildup of $43,458 and accounts receivable increase of $10,159, while cash and equivalents fell 13% QoQ to $330,271.

• ·Acquisitions of $13,329 net of cash acquired in Q1 2026.
• ·Share repurchases of 304,321 shares for $12,267 in Q1 2026.
• ·Weighted average basic shares outstanding decreased to 36,683,938 from 40,020,265 YoY.
• ·Basic EPS $1.04, up from $0.68 YoY.

07-05-2026

Hennessy Capital Investment Corp. VII announced a proposed business combination with ONE Nuclear Energy LLC, targeting closing in Q2 2026 with post-merger listing on NASDAQ under ticker ONEN. ONE Nuclear develops, owns, and operates baseload power using fast-track gas generation and advanced nuclear SMRs, securing three priority development sites in Texas, New Mexico, and Washington with 1 GW targeted online by end of 2029 from a 15 GW total potential pipeline across 75+ sites. The management team has delivered over $50 billion in infrastructure projects, supported by strategic partners including Rolls-Royce, BP Energy, and Black & Veatch.

• ·LOI signed in July 2025; raised Hennessy VII in late January 2025
• ·First gas revenues projected for 2028; Texas site: 1 GW gas by 2029, 2 GW nuclear SMR by 2034; New Mexico: initial 1 GW gas expandable to 10 GW; Washington: up to 6 GW SMR
• ·Strategic relationships with Rolls-Royce (gas and SMR), Westinghouse, X-energy, TerraPower; BP Energy for offtake; Black & Veatch for EPC
• ·Sites selected for >1000 acres, gas/water access, proximity to data centers in ERCOT (Texas), high-growth areas

07-05-2026

Lincoln Financial reported a Q1 2026 net loss available to common stockholders of $211 million ($1.10 per diluted share), improved from $756 million ($4.41 per share) in Q1 2025, while adjusted operating income available to common stockholders rose to $326 million ($1.66 per share) from $280 million ($1.60 per share). Strong performances included Life Insurance operating income up to $41 million (from a $16 million loss), Group Protection up 11% to $112 million, and Retirement Plan Services up 26% to $43 million; however, Annuities operating income declined 5% to $275 million and net outflows widened to $2.2 billion. Holding company available liquidity increased to $805 million net of prefunding.

• ·RBC ratio estimated >420% as of Q1 2026
• ·Alternative investment income after-tax $102 million in Q1 2026 (up from $59 million Q1 2025)
• ·Book value per share excluding AOCI $71.06 as of Q1 2026 (up from $67.04 Q1 2025)
• ·Net unrealized loss on AFS securities improved to $9.1 billion pre-tax from $9.4 billion pre-tax YoY
• ·Group Protection premiums $1,399 million Q1 2026, up 2% YoY but adjusting for large case lapse up 3.4%

07-05-2026

Haemonetics reported Q4 FY26 revenue of $346.4 million, up 4.8% YoY with Hospital segment growth of 8.0%, but Plasma up only 2.8%, Blood Center 0.7% (flat), and full-year FY26 revenue down 2.0% to $1.334 billion. GAAP results showed a Q4 net loss of $20.1 million and $(0.44) EPS due to impairments on Attune Medical assets, while adjusted EPS rose 4.0% YoY to $1.29. The company repurchased $100 million in shares, ended with $245.4 million cash, and guided FY27 organic revenue growth to 3-6% with mid-single-digit decline in Blood Center.

• ·Q4 FY26 GAAP gross margin: 57.2% (down from 58.4% YoY)
• ·Q4 FY26 adjusted gross margin: 59.7% (down 50 bps YoY)
• ·FY27 guidance: Reported revenue growth 4-7%, adjusted operating margin expansion 50-100 bps YoY, adjusted EPS comparable to revenue growth
• ·Vivasure acquisition in January 2026 had no impact on organic revenue growth
• ·Attune Medical-related charges: impairment of intangible assets and provision for pre-acquisition inventory

07-05-2026

Century Communities, Inc. held its Annual Meeting of Stockholders on May 6, 2026, with a strong quorum of 27,486,313 shares present, representing 94.7% of the 29,025,462 outstanding shares. All seven director nominees were elected with majority support (ranging from approximately 90% for John P. Box to 98% for Dale Francescon), the appointment of Ernst & Young LLP as independent auditors was ratified with 99% approval, and the advisory vote on executive compensation passed with about 88% in favor despite 3,000,529 votes against. No proposals failed, indicating robust shareholder approval across the board.

• ·Proposal 1 Director Votes - John P. Box: 23,887,907 For, 2,522,092 Against; James M. Lippman: 25,269,142 For, 1,140,857 Against
• ·Proposal 2 Auditor Ratification: 27,243,512 For, 232,820 Against, 9,981 Abstained
• ·Proposal 3 Exec Comp: 23,404,448 For, 3,000,529 Against, 13,477 Abstained

07-05-2026

Avient reported Q1 2026 sales of $847.4 million, up 3% YoY from $826.6 million, driven by a 5% favorable FX impact implying ~2% organic decline; adjusted EPS grew 9% to $0.83 exceeding guidance, with adjusted EBITDA margins expanding 20 basis points to 17.7%. GAAP EPS improved to $0.61 from a ($0.22) loss, aided by prior-year special items including a large ERP impairment. Full-year 2026 guidance remains unchanged at adjusted EPS $2.93-$3.17 and adjusted EBITDA $555-$585 million, with Q2 adjusted EPS guided at $0.89 (11% YoY growth), though H2 outlook is less certain.

• ·Q1 2026 special items after-tax: $5.5M expense ($0.06 per share); Q1 2025: $75.7M expense ($0.82 per share) including $86.3M ERP impairment
• ·Cash dividends declared: $0.2750 per share (Q1 2026) vs $0.2700 (Q1 2025)
• ·Weighted-average diluted shares: 91.9M (Q1 2026) vs 91.5M (Q1 2025)
• ·Total assets: $5,944.8M (Mar 31, 2026) vs $6,025.6M (Dec 31, 2025)

07-05-2026

Celsius Holdings reported record Q1 2026 revenue of $782.6 million, up 138% YoY from $329.3 million, driven by Alani Nu ($368.1 million revenue) and Rockstar Energy ($66.6 million), with North America revenue surging 144% to $747.3 million and International up 55% to $35.3 million. However, gross margin declined 400 basis points to 48.3% due to lower-margin acquired brands, and Rockstar Energy retail sales fell 13% YoY while CELSIUS brand revenue grew modestly 6% YoY. Net income increased 148% to $110.1 million, adjusted EBITDA rose 181% to $195.5 million, and the company repurchased $24.1 million in shares.

• ·Celsius Holdings portfolio contributed 45% of the zero-sugar U.S. energy category’s $800 million growth in Q1 2026.
• ·Approximate 20.9% dollar share of the U.S. RTD energy category in Q1 2026.
• ·CELSIUS brand held 9.9% dollar share, Alani Nu 9.0%, Rockstar Energy 2.0% in U.S. RTD energy category L13W ended 3/29/2026.
• ·SG&A expenses increased 95% to $234.6 million (30.0% of revenue vs 36.5% prior year); adjusted SG&A 26.4% of revenue.
• ·Cash and cash equivalents increased to $549.2 million from $398.9 million at year-end 2025.

07-05-2026

Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M, down 18% YoY from $8.8M, amid rising operating expenses with R&D up 23% to $57.8M and G&A up 33% to $13.5M, resulting in a net loss attributable to common stockholders of $69.2M versus $53.3M YoY. However, the company completed its IPO raising $369.3M in net proceeds, boosting cash and equivalents to $160.6M and marketable securities to $356.1M, with total assets reaching $625.7M and flipping stockholders' equity to a positive $514.8M from a $616.0M deficit at year-end 2025.

• ·Net cash used in operating activities increased to $80.4M in Q1 2026 from $53.2M YoY.
• ·Net cash used in investing activities was $259.9M in Q1 2026, driven by $321.2M purchases of marketable securities.
• ·Weighted average common shares outstanding: 64,871,295 in Q1 2026 vs 32,791,905 in Q1 2025.
• ·Property and equipment, net declined to $27.8M from $29.2M QoQ.

07-05-2026

First Advantage reported record Q1 2026 revenues of $385.2 million, up 8.6% YoY from $354.6 million, with Adjusted EBITDA rising 14.3% to $105.3 million (27.3% margin) and Adjusted Net Income up 48.0% to $45.1 million. GAAP net income improved to $2.2 million (0.6% margin) from a $41.2 million loss in Q1 2025, though the margin remains modest. The company repurchased $19.5 million in shares during the quarter (plus $13.8 million subsequently) and made voluntary debt prepayments totaling $50 million early in 2026, while reaffirming full-year guidance.

• ·Customer retention rate of 97%.
• ·Share repurchase program authorization of $100 million.
• ·Positive momentum in retail & e-commerce, transportation & logistics, and gig economy verticals.
• ·Conference call held on May 7, 2026, at 8:30 a.m. ET.

07-05-2026

Ares Commercial Real Estate Corp reported a Q1 2026 GAAP net loss of $(9.6) million or $(0.17) per diluted common share, compared to a $9.3 million profit or $0.17 per share in Q1 2025, primarily due to an $11.1 million provision for current expected credit losses and $3.3 million in realized loan losses; however, Distributable Earnings were positive at $3.2 million or $0.06 per share. The loan portfolio grew with $294 million in new commitments closed during the quarter and total assets increased 13.4% QoQ to $1.84 billion, while net interest margin declined 18.8% YoY to $7.5 million. The company declared a $0.15 per share dividend for Q2 2026, matching prior quarters, and subsequently closed $95 million in additional commitments.

• ·Provision for current expected credit losses of $11.1 million in Q1 2026 vs reversal of $5.3 million in Q1 2025
• ·Realized losses on loans of $3.3 million in Q1 2026
• ·Q2 2026 dividend payable July 15, 2026 to stockholders of record June 30, 2026
• ·Conference call held May 7, 2026 at 12:00 p.m. ET

07-05-2026

Marcus & Millichap reported first quarter 2026 total revenue of $171.5 million, up 18.2% YoY from $145.0 million, with brokerage commissions increasing 11.7% to $138.1 million and financing fees surging 48.1% to $26.8 million. However, total operating expenses rose to $177.2 million from $162.7 million, resulting in an ongoing net loss of $3.1 million ($0.08 per diluted share), improved from $4.4 million ($0.11 per diluted share), while Adjusted EBITDA turned positive at $2.9 million from $(8.7) million. The company repurchased 895,532 shares for $23.5 million and has approximately $90 million available under its stock repurchase program.

• ·Total sales volume of $12.1 billion in Q1 2026, including $7.9 billion brokerage (1,348 transactions) and $3.1 billion financing (398 transactions).
• ·Semi-annual dividend of $0.25 per share declared February 10, 2026, paid April 3, 2026.
• ·Board approved additional $70 million for share repurchases on April 30, 2026; ~$90 million available.
• ·1,808 investment sales and financing professionals as of December 31, 2025.
• ·Cost of services increased $15.3 million YoY to 60.5% of revenue (down 40 bps YoY); SG&A flat at $71.2 million.

07-05-2026

Gyre Therapeutics reported Q1 2026 revenue of $22.5 million, up 2% YoY to $22.5M from $22.1M, driven by Contiva ($0.8M, up from $0.3M) and new Etorel ($0.7M) sales, though ETUARY declined 3% YoY to $21.0M from $21.7M; full-year 2026 revenue guidance of $100.5-111.0 million was affirmed. The company completed its ~$300 million all-stock acquisition of Cullgen in May 2026, expanding into targeted protein degradation for inflammatory diseases and cancers, alongside submitting an NDA for F351 (hydronidone) for CHB-associated liver fibrosis, which received NMPA priority review. However, operating expenses rose sharply (S&M +30%, R&D +118%, G&A +46%), resulting in an operating loss of $9.4 million versus prior income of $2.3 million and net loss of $9.9 million versus prior income of $3.7 million.

• ·NMPA CDE granted priority review designation to F351 NDA in March 2026; currently under completeness review.
• ·Phase 3 pneumoconiosis trial (272 patients) completed enrollment in 2025; topline data expected Q3 2026.
• ·GAAP basic EPS for Q1 2026: $(0.10).
• ·Non-GAAP adjusted net loss Q1 2026: $4.2M vs adjusted net income $2.9M in Q1 2025.
• ·Gyre owns 69.7% equity interest in Gyre Pharmaceuticals.

07-05-2026

ATN International reported Q1 2026 revenue of $182.2 million, up 1.6% YoY, operating income of $11.7 million, up $9.0 million YoY, and Adjusted EBITDA of $48.6 million, up 10% YoY, driven by revenue growth in carrier services and ancillary revenues alongside cost containment. However, net cash provided by operating activities declined 17% to $29.8 million due to working capital timing, high-speed broadband subscribers grew only 3% to 142,500, and total mobile subscribers were essentially flat at 0.2% YoY growth to 386,400. The company reaffirmed its 2026 Adjusted EBITDA outlook of $190-200 million excluding the US tower portfolio sale, which is expected to reduce it by $6-8 million upon initial Q2 closing generating $250-270 million in proceeds.

• ·Net Debt Ratio improved to 2.30x from 2.52x YoY.
• ·Quarterly dividend of $0.275 per share paid on April 10, 2026.
• ·No share repurchases during Q1 2026.
• ·2026 full-year capex outlook $105-115 million (net of reimbursable).
• ·Subsequent tower sale closings expected to generate $27-47 million over 12 months post-initial closing.

07-05-2026

News Corporation disclosed in its 8-K filing information provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, under which the company is authorized to acquire up to $1 billion in aggregate of its Class A common stock (NWSA) and Class B common stock (NWS). The disclosures are attached as Exhibits 99.1 and 99.2, covering daily transaction updates as required by ASX rules. The filing notes forward-looking statements about potential repurchases subject to market conditions and other factors.

• ·Date of earliest event reported: May 6, 2026
• ·Filing signed and dated: May 7, 2026
• ·Securities registered: Class A Common Stock (NWSA) and Class B Common Stock (NWS) on The Nasdaq Global Select Market

07-05-2026

LifeStance Health Group reported first quarter 2026 revenue of $403.5 million, up 21% YoY from $333.0 million, driven by 18% higher visit volumes to 2.5 million and an 11% increase in clinician base to 8,349. Net income improved to $14.2 million from $0.7 million, income from operations rose to $22.3 million from $1.6 million, Center Margin grew 24% to $135.9 million, and Adjusted EBITDA increased 48% to $51.1 million. The company generated $33.1 million in net cash from operations and $22.3 million in free cash flow, while raising full-year 2026 guidance to $1.640-$1.680 billion in revenue and $200-$220 million in Adjusted EBITDA.

• ·Sequential net clinician increase of 309 in Q1 2026
• ·Operates across 33 states and more than 550 centers
• ·Q2 2026 guidance: revenue $405-$425 million, Center Margin $135-$147 million, Adjusted EBITDA $50-$60 million
• ·Cash decreased sequentially to $194.8 million from $248.6 million as of Dec 31, 2025

07-05-2026

Avalo Therapeutics entered into an underwriting agreement on May 5, 2026, to issue and sell 19,730,000 shares of common stock at $17.75 per share and 1,400,000 pre-funded warrants at $17.749 each, with the underwriters fully exercising their option for an additional 3,169,500 shares, expecting net proceeds of approximately $405.0 million. As of March 31, 2026, the company had preliminary cash, cash equivalents, and short-term investments of $82.0 million, and together with the offering proceeds, expects to fund operations into 2029, primarily for advancing abdakibart through Phase 3 topline data release. The offering is expected to close on May 7, 2026, subject to customary conditions.

• ·Pre-Funded Warrants exercisable at $0.001 per share or via cashless exercise, with ownership limit initially set at 4.99% or 9.99%, adjustable up to 19.99% upon 61 days' notice.
• ·Underwriting option exercisable for 30 days after Prospectus Supplement dated May 5, 2026.
• ·Prospectus Supplement filed with SEC on May 6, 2026, under Form S-3 effective January 20, 2026.

07-05-2026

Gold.com reported exceptional Q3 FY2026 results with revenues surging 244% YoY to $10.351 billion and 60% QoQ from $6.477 billion, driven by record metal prices and volatility, alongside net income of $59.5 million (up 796% YoY from a $8.5 million loss) and EBITDA of $103.4 million (up 7,939% YoY). Gross profit rose 331% YoY to $176.6 million with margin expansion to 1.71%. However, DTC new customers declined sharply 67% YoY to 292,900, secured loans outstanding fell 31% YoY to 337, and gold ounces sold dipped 3% QoQ to 527,000.

• ·CyberMetals new customers declined 38% YoY to 1,300.
• ·Secured loans receivable increased 46% YoY to $126.0 million despite fewer loans.
• ·Nine months FY2026 revenues up 142% YoY to $20.508 billion; net income $70.2 million (up 903% YoY).
• ·Tether/TPM investment: 3,370,787 shares at $44.50/share; first tranche Feb 6, 2026; second tranche May 5, 2026 following regulatory clearance.
• ·Monex acquisition at start of Q3; Sunshine Mint addition at start of Q4.

07-05-2026

Houlihan Lokey reported record fiscal year 2026 revenues of $2.62 billion, up approximately 10% YoY from $2.39 billion, driven by Corporate Finance (+14%) and Financial and Valuation Advisory (+8%) growth, though Financial Restructuring declined 3% YoY; diluted EPS rose to $6.22 from $5.82. However, Q4 FY2026 revenues fell 5% YoY to $636 million from $666 million, with Financial Restructuring dropping 33% despite Corporate Finance (+5%) and FVA (+3%) gains; Q4 diluted EPS declined to $1.47 from $1.76. The company announced a 16.7% quarterly dividend increase to $0.70 per share and repurchased 301 thousand shares.

• ·Compensation ratio stable at 64.3% for FY2026 (GAAP) vs 63.8% FY2025.
• ·Non-compensation expenses increased to $407M FY2026 from $363M FY2025.
• ·Effective tax rate 24.6% FY2026 vs 24.8% FY2025.
• ·Share repurchase program ongoing; $1.36B unrestricted cash as of Mar 31, 2026.
• ·Dividend payable June 15, 2026 to shareholders of record June 1, 2026.

07-05-2026

EPAM reported first quarter 2026 revenues of $1.400 billion, up 7.6% year-over-year, though organic constant currency growth was only 3.7%; GAAP income from operations rose 17.6% to $116.8 million (8.3% margin), and non-GAAP to $200.7 million (14.3% margin). GAAP diluted EPS increased 18.8% to $1.52 and non-GAAP to $2.86 (up 18.7%), with $324 million spent on share repurchases; however, operating cash flow was a use of $36.4 million versus $24.2 million provided last year, cash balances fell 19.9% to $1.043 billion, and delivery headcount declined 0.2% to 56,500. Full-year 2026 revenue growth guidance was updated to 4.0%-6.5% (organic constant currency 2.5%-5.0%), with GAAP diluted EPS expected at $8.29-$8.59.

• ·Total assets decreased to $4,703,451 thousand from $4,902,136 thousand as of Dec 31, 2025.
• ·Long-term debt increased to $165,000 thousand from $25,034 thousand QoQ.
• ·Q2 2026 revenue guidance $1.400B to $1.415B (4.0% YoY growth at midpoint).
• ·FY2026 GAAP operating margin guidance 10%-11%, non-GAAP 15%-16%.

07-05-2026

On May 5, 2026, Fruci & Associates II, PLLC resigned as Quest Water Global, Inc.'s independent accountant at the company's request, with no replacement engaged yet. Prior audit reports for fiscal years ended December 31, 2024 and 2023 contained no adverse opinions or disagreements but noted substantial doubt about the company's ability to continue as a going concern and ongoing material weaknesses in internal control over financial reporting. The board, acting as audit committee, approved the change, and Fruci's concurring letter is filed as Exhibit 16.1.

• ·Resignation effective May 5, 2026; Form 8-K filed May 7, 2026 under Items 4.01 and 9.01.
• ·No disagreements on accounting principles, practices, disclosure, or auditing scope during FY 2023, 2024, and interim through May 5, 2026.
• ·No reportable events except discussions on material weaknesses in internal controls.

07-05-2026

On April 30, 2026, Grayscale Investments Sponsors, LLC, the manager of Grayscale CoinDesk Crypto 5 ETF (GDLC), completed its quarterly portfolio rebalancing in accordance with the CoinDesk 5 Index Methodology, with no new tokens added or removed, maintaining Bitcoin, Ethereum (Ether), XRP, Solana (SOL), and BNB as components. As of May 1, 2026, post-rebalancing weights are 75.99% Bitcoin, 13.47% Ether, 4.16% XRP, 4.04% BNB, and 2.34% SOL. This routine rebalancing adjusts holdings to match index weightings, with additional details in periodic SEC filings.

• ·Each Fund Share represents 0.0003 Bitcoin, 0.0021 Ether, 1.0505 XRP, 0.0023 BNB, and 0.0098 SOL as of May 1, 2026.
• ·Index rebalanced quarterly, beginning 30 days before the last business day of January, April, July, and October.
• ·Annual Report on Form 10-K filed September 5, 2025.

07-05-2026

Lumen Technologies' indirect subsidiary, Level 3 Financing, Inc., announced a $1 billion private offering of 7.500% Senior Notes due 2037, with proceeds intended to fund cash tender offers for up to $750 million aggregate purchase price of existing notes issued by Level 3 Financing, Lumen, and Qwest Capital Funding, Inc. The tender targets include various Level 3 Notes (e.g., 4.250% due 2028), Lumen Notes (e.g., 6.875% due 2028), and QCF Notes, with the offering expected to close on May 21, 2026, subject to customary conditions. No operational or financial performance metrics were disclosed.

• ·Tender offers prioritize Level 3 Notes first, then Lumen Notes, then QCF Notes.
• ·Offering not registered under Securities Act of 1933; not an offer to sell or solicitation in any jurisdiction where unlawful.
• ·Press releases filed as Exhibits 99.1 (proposed offering and tenders) and 99.2 (pricing announcement), both dated May 6, 2026.
• ·Date of earliest event reported: May 6, 2026; Form 8-K filed May 7, 2026.

07-05-2026

InMed Pharmaceuticals Inc. (INM) filed an 8-K on May 7, 2026, disclosing under Regulation FD its financial results for Q3 fiscal year 2026, ended March 31, 2026. The results are detailed in furnished Exhibit 99.1, a news release dated May 6, 2026. No specific financial metrics or performance changes are provided in the filing body.

• ·Filing intended to satisfy Regulation FD obligations; information in Item 7.01 and Exhibit 99.1 is furnished, not filed.
• ·Registrant is an emerging growth company.

07-05-2026

Faraday Future announced plans to upgrade the FX Super One MPV to a more competitive 800V BEV or accelerate the AIHER hybrid project, pausing the original 400V cooperation and potentially delaying mass-production deliveries until strategic financing is secured. The company has shipped 68 EAI robots as of April 30, 2026, achieving positive gross margins, with May shipments accelerating toward a first-quarter target of 200 units and cumulative 2026 shipments exceeding 1,000 units, supported by $45M in recent financing. This strategic shift prioritizes robotics ramp-up to reduce near-term cash outflows and financial risk, but underscores dependency on future funding and execution challenges.

• ·Super One 800V BEV delivery timeline post-funding: first phase 6-9 months, second 12-15 months, third 21-24 months
• ·AIHER hybrid delivery timeline post-funding: first phase 9-12 months, second 21-24 months, third 24-28 months
• ·Press release dated May 5, 2026; SEC filing May 7, 2026

07-05-2026

Stabilis Solutions reported Q1 2026 revenues of $10.4 million, down 40.2% YoY from $17.3 million due to completion of marine and power generation contracts, resulting in a net loss of $4.1 million (vs. $1.6 million loss) and Adjusted EBITDA loss of $0.7 million (vs. $2.1 million profit). However, aerospace revenues grew 31% YoY, cash flow from operations surged to $12.4 million (from $1.0 million) driven by $15.0 million customer advance payments, and the company secured a $200 million 2-year LNG supply contract for a U.S. data center starting Q1 2027. Management anticipates significant improvement in H2 2026 from demand in aerospace, industrial, and data center markets.

• ·Q1 2026 capex of $5.3 million on fixed assets.
• ·Total assets increased to $115.2 million from $83.1 million at year-end 2025, driven by $14.7 million noncurrent deferred revenue.
• ·Conference call scheduled for May 7, 2026 at 9:00 a.m. ET.

07-05-2026

Carlyle Group Inc. reported unaudited Q1 2026 U.S. GAAP results including a loss before provision for income taxes of $179 million and a 70.5% margin on that loss. Despite the loss, CEO Harvey M. Schwartz emphasized continued momentum with exceptional growth at Carlyle AlpInvest, strong fundraising starts, and a record quarter for U.S. Buyout realizations, bolstering confidence in 2028 targets. The firm declared a $0.35 quarterly dividend per common share and oversees $475 billion in assets under management as of March 31, 2026.

• ·Dividend record date: May 18, 2026; payable May 28, 2026.
• ·Conference call: 8:30 a.m. EDT on May 7, 2026, via ir.carlyle.com.
• ·Full Q1 2026 results presentation available at ir.carlyle.com.

07-05-2026

Kinetik Holdings Inc. reported record Q1 2026 Adjusted EBITDA of $251.2 million, Distributable Cash Flow of $180.8 million, and Free Cash Flow of $101.4 million, driven by strong Midstream Logistics performance up 12% YoY to $178.9 million. However, the company recorded a net loss of $5.1 million, Pipeline Transportation Adjusted EBITDA declined nearly 17% YoY to $78.0 million due to the EPIC Crude divestiture, total operating revenues fell to $409.976 million from $443.263 million, and processed natural gas volumes grew only 1% YoY to 1.81 Bcf/d amid 170 Mmcf/d of Waha price-related shut-ins. Full-year 2026 guidance remains affirmed at $950-1,050 million Adjusted EBITDA and $450-510 million capital expenditures, despite revising processed gas volume growth to low- to mid-single digits due to higher estimated curtailments of 220 Mmcf/d.

• ·Q1 Waha price-related processed gas volume shut-ins: 170 Mmcf/d
• ·Full-year 2026 estimated Waha price-related production shut-ins: 220 Mmcf/d (up from original 100 Mmcf/d assumption)
• ·Durango amendments cover ~75% of legacy volumes, extending to mid/late 2030s, adding 12,000 gross acres (+25%)
• ·Kings Landing project approvals received for 20 Mmcf/d acid gas capacity, in-service by year-end 2026
• ·ECCC Pipeline nearing completion, in-service Q2 2026
• ·YTD April Waha Hub gas daily average: negative $2.37 per Mmbtu
• ·Dividend per share: $0.81
• ·Dividend Coverage Ratio: 1.4x
• ·Net Debt to Adjusted EBITDA Ratio: 3.9x
• ·Leverage Ratio: 3.9x

07-05-2026

PTC Inc. reported robust revenue growth for the three months ended March 31, 2026, up 22% YoY to $774M, driven by 43% increase in license revenue to $363M and 10% growth in support and cloud services to $388M, though professional services declined 17% to $24M. Net income surged to $591M from $163M, boosted by $466M in other income from a business divestiture, while operating income rose 32% to $296M; for the six months, revenue increased 22% to $1,460M but sales and marketing expenses were flat at $281M and G&A expenses jumped 50%. Significant stock repurchases of $826M reduced shares outstanding by 4,682 to 115,498.

• ·Cash and cash equivalents increased to $439M from $184M at September 30, 2025.
• ·Total assets decreased slightly to $6,537M from $6,617M at September 30, 2025.
• ·Deferred revenue declined to $757M current from $812M at September 30, 2025.
• ·Net cash provided by operating activities $591M for six months ended March 31, 2026, up from $520M.
• ·Gain on divestiture of businesses $465M in six months ended March 31, 2026.
• ·Accumulated other comprehensive loss worsened to $(93M) from $(81M) at September 30, 2025.

07-05-2026

For the three months ended March 31, 2026, Nuveen Churchill Direct Lending Corp. (NCDL) reported total investment income of $46,258, down 14% YoY from $53,586, with net investment income declining 27% to $20,044 amid higher expenses and lower interest income. Net increase in net assets from operations fell 42% YoY to $8,687, driven by realized losses of $3,289 and unrealized depreciation of $8,068 (an improvement from $13,534 YoY), resulting in net assets of $864,112, down 1% QoQ from $875,180 and 6% YoY from $920,020, with NAV per share at $17.50 versus $17.72 QoQ. Investments grew slightly 1% QoQ to $1,975,862 at fair value, while distributions declared totaled $19,755.

• ·Cash and cash equivalents decreased to $50,400 as of March 31, 2026 from $62,481 at December 31, 2025.
• ·Total debt increased to $1,137,789 as of March 31, 2026 from $1,115,052 at December 31, 2025.
• ·Net cash used in operating activities was $13,738 for Q1 2026, compared to $8,808 used in Q1 2025.
• ·Investments represent 228.66% of net assets as of March 31, 2026.

07-05-2026

Ponce Financial Group, Inc. reported Q1 2026 net income of $8,623 thousand, up 44.7% YoY from $5,959 thousand, driven by net interest income growth of 27.1% YoY to $28,226 thousand amid higher loan interest income, while total assets increased 2.4% QoQ to $3,300,757 thousand with loans up 3.8% to $2,698,649 thousand and deposits up 4.2% to $2,133,795 thousand. However, provision for credit losses deteriorated to a $1,656 thousand expense from a $285 thousand benefit YoY, non-interest income fell 14.2% YoY to $2,042 thousand, non-interest expense rose 2.1% to $17,240 thousand, and cash equivalents declined 7.1% QoQ to $117,246 thousand.

• ·Allowance for credit losses on loans: $26,238 thousand at March 31, 2026 (up from $25,449 thousand at Dec 31, 2025)
• ·Total non-performing loans recorded investment: $20,351 thousand at March 31, 2026 (down from $22,923 thousand at March 31, 2025)
• ·Basic EPS: $0.36 for Q1 2026 (up from $0.25 YoY)
• ·Stockholders' equity: $551,363 thousand at March 31, 2026 (up 1.8% QoQ from $541,549 thousand)

07-05-2026

Arthur J. Gallagher & Co. reported total revenues of $4,758M for Q1 2026, up 28% YoY from $3,727M, driven by commissions (+39% to $3,123M) and fees (+23% to $1,212M), with net earnings rising 16% to $823M and diluted EPS to $3.16. However, interest income, premium finance revenues and other income declined sharply 65% to $86M from $247M, and comprehensive earnings attributable to controlling interests fell to $781M from $921M due to foreign currency translation losses and changes in derivative investments. Operating cash flow increased 10% to $957M, while net cash used in investing activities was $238M including $289M for acquisitions, and financing activities used $723M net amid $310M stock repurchases.

• ·Acquired net assets totaling $334M from KGC ($220M net) and eight other acquisitions ($114M net).
• ·Dividends declared per common share increased to $0.70 from $0.65 YoY.
• ·Fiduciary assets increased to $33,873M at March 31, 2026 from $26,899M at December 31, 2025.

07-05-2026

For the three months ended March 31, 2026, Invesco CurrencyShares Canadian Dollar Trust reported total assets of $84,074,863, up 12.2% from $74,931,453 at December 31, 2025, driven by net share purchases of 150,000 shares adding $10,701,981 to redeemable capital shares, reaching 1,200,000 shares outstanding valued at $84,046,301. However, interest income declined 45.0% YoY to $103,924 from $189,029, leading to net comprehensive income of $23,508, down 81.7% YoY from $122,723, with sponsor's fees rising 21.3% to $80,416. Shares outstanding increased, but earnings per share fell to $0.02 from $0.12 YoY.

• ·Net cash provided by operating activities $22,858 in Q1 2026 vs $142,646 in Q1 2025.
• ·Net cash provided by financing activities $10,644,864 in Q1 2026 vs $6,757,702 in Q1 2025.
• ·Effect of exchange rate on cash $(1,527,180) in Q1 2026 vs $(154,441) in Q1 2025.
• ·Distributions $(23,089) in Q1 2026 vs $(142,552) in Q1 2025.

07-05-2026

For Q1 2026, Invesco CurrencyShares Australian Dollar Trust reported total assets of $101.8M, up 14% QoQ from $89.3M, driven by share purchases increasing outstanding shares to 1.5M from 1.3M. Interest income rose 25% YoY to $360,147 with net income up 17% to $264,192; however, EPS declined 14% YoY to $0.19 due to higher weighted-average shares, and sponsor fees increased 54% YoY to $95,955.

• ·Net cash provided by operating activities declined slightly to $222,878 in Q1 2026 from $230,528 in Q1 2025.
• ·Proceeds from share purchases were $13,842,616 in Q1 2026 vs $3,111,472 in Q1 2025.
• ·Distributions remained flat at approximately $235K YoY.

07-05-2026

Total assets grew 68% QoQ to $1,217,547,269 as of March 31, 2026 from $725,843,982 at December 31, 2025, driven by net share purchases of 16,350,000 shares contributing $438,500,752 to shareholders' equity, which rose to $1,216,957,097; NAV per share increased 6.7% to $27.26. Net income swung to a profit of $55,653,744 in Q1 2026 from a $11,250,436 loss in Q1 2025, boosted by $44,891,988 unrealized gains on commodity futures and $5,324,603 realized gains. However, total income declined 19% YoY to $6,981,040, net investment income fell 20% to $5,437,153, and specific commodity futures like NYB-ICE Cocoa and Coffee posted unrealized depreciation of $14,891,701 and $6,684,502 respectively.

• ·Deposit with Commodity Broker decreased to $81,775,836 from $134,602,431 QoQ.
• ·Net realized gain on commodity futures contracts $5,324,603 in Q1 2026 vs $83,727,907 in Q1 2025.
• ·Unrealized depreciation on CBOT Soybean Meal: $1,489,989; NYB-ICE Sugar: $2,017,972.